Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All curcumin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition

Hidayah et al., International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724
Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
In Silico study showing binding of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin to the SARS-CoV-2 nucleocapsid protein. Authors find curcumin has the strongest predicted binding affinity. All compounds showed suitable pharmacokinetic properties. Binding is predicted to inhibit viral genome replication and transcription by disrupting ribonucleoprotein complex formation.
In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spike Note A, Nag, Moschovou, Kandeil, Singh (B) (and specifically the receptor binding domain Note B, Kant, Srivastava, Eleraky), Mpro Note C, Moschovou, Kandeil, Srivastava, Naderi Beni, Rajagopal, Rampogu, Sekiou, Singh, Winih Kinasih, Thapa, Bahun, Eleraky, RNA-dependent RNA polymerase Note D, Singh (C), Eleraky, ACE2 Note E, Singh (B), Thapa, Alkafaas, nucleocapsid Note F, Hidayah, Suravajhala, and nsp10 Note G, Suravajhala proteins. In Vitro studies demonstrate inhibition of the spike Note A, Mohd Abd Razak (and specifically the receptor binding domain Note B, Goc (B)), Mpro Note C, Bahun, Guijarro-Real, Mohd Abd Razak, Wu, ACE2 Note E, Goc (B), and TMPRSS2 Note H, Goc (B) proteins. In Vitro studies demonstrate efficacy in Calu-3 Note I, Bormann, A549 Note J, Mohd Abd Razak, 293T Note K, Zhang, HEK293-hACE2 Note L, Nittayananta, Wu, 293T/hACE2/TMPRSS2 Note M, Septisetyani, and Vero E6 Note N, Bormann, Eleraky, Kandeil, Leka, Mohd Abd Razak, Nittayananta, Singh, Teshima, Marín-Palma cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants Kant, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells Marín-Palma, and alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress Zhang.
Hidayah et al., 6 Feb 2024, peer-reviewed, 3 authors. Contact: rizkanurulh@student.ub.ac.id, dewi.santosa@ub.ac.id, roihatulmutiah@gmail.com.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperCurcuminAll
Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition
Rizka Nurul Hidayah, Dewi Santosaningsih, Roihatul Muti’ah
doi:10.1063/5.0197724
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a higher reproduction rate (R0) than SARS-CoV-1 is assessed to be 2.5 contrasted with 2.0-3.0 for SARS-CoV, indicating a much faster spread. During the replication process, the viral ribonucleic acid (RNA) genome is bound to the nucleocapsid and packaged into a ribonucleoprotein complex (RNP) which is essential for maintaining RNA conformation for genome replication and copy. Antiviral agents are given to prevent the replication area from expanding. In silico simulation was used to predict an interaction between Curcuma longa compound as an Antiviral agent by inhibiting viral RNA transcription and replication through inhibiting the activity of the nucleocapsid during the screening of a new compound as a drug candidate. The Nucleocapsid structures were used to create the protein target from Protein Data Bank. PubChem online tool was used to determine the structure of Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, and Cyclocurcumin as ligands. With the help of software like pkCSM, Protox, and SwissADME, these structures are analyzed for pharmacokinetics and physicochemistry interactions. To predict the most probable compliance of how the ligand will tie to the macromolecule evaluated through the action of the compound in light of the Rerank Score using the Molegro Virtual Docker 6.0 software. When curcumin binds to 6VYO, it has the lowest bond energy (-73,8743 Kcal/mol) than the native ligand and comparison drug Chloroquine (-60.438 Kcal/mol and -59.062 Kcal/mol, respectively). These findings tend to inhibit the role of nucleocapsids in the binding of viral RNA genomes and the packaging process into ribonucleoprotein complexes (RNPs), leading to the prevention of viral infection, replication, and packaging processes of the virus.
References
Allen, Mervin, Mahmoud, Bender, None, J Cheminform, doi:10.1186/s13321-019-0356-5
Ashraf, Sultan, Campus, Alam, Darul Ehsan, None, International Journal of Green Pharmacy
Askarizadeh, Barreto, Henney, Majeed, Sahebkar, None, International Journal of Pharmaceutics, doi:10.1016/j.ijpharm.2020.119476
Cevik, Kuppalli, Kindrachuk, Peiris, None, The BMJ
Chen, Li, Tian, Li, Luo et al., None, Journal of Computational Biology, doi:10.1089/cmb.2019.0323
Chen, None, Research on Chemical Intermediates, doi:10.1007/s11164-016-2583-y
Cong, None, J Virol, doi:10.1128/JVI.01925-19
Dona, Frimayanti, Ikhtiarudin, Iskandar, Maulana et al., None, Jurnal Sains Farmasi & Klinis, doi:10.25077/jsfk.6.3.243-249.2019
Fu, Chen, Zhang, Yu, Yang, None, Int. J. Mol. Med
Fu, Chen, Zhang, Yu, Yang, None, Int. J. Mol. Med, doi:10.3892/ijmm.2017.2926
Guan, None, New England Journal of Medicine, doi:10.1056/NEJMoa2002032
Hamm, None, Regulatory Toxicology and Pharmacology, doi:10.1016/j.yrtph.2021.105007
Kang, None, Acta Pharm Sin B
Khan, None, Comput Struct Biotechnol J, doi:10.1016/j.csbj.2020.08.006
Kwarteng, Asiedu, Sakyi, Asiedu, None, Biomedicine and Pharmacotherapy
Lang, Chen, Li, Li, None, Life Sciences, doi:10.1016/j.lfs.2020.118754
Marazzi, Francés-Monerris, Mourer, Pasc, Monari, None, Physical Chemistry Chemical Physics, doi:10.1039/C9CP06565B
Mazhir, Ali, Kadhim, Majeed, None, Journal of Physics
Megasari, None, PLoS One, doi:10.1371/journal.pone.0251234
Mitsuwan, None, Int J Parasitol Drugs Drug Resist, doi:10.1016/j.ijpddr.2020.11.001
Oyesakin, George, Fadare R Y, Idris, Fadare, None, Am J Pharmacol Sci
Petersen, None, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30484-9
Rim, None, Toxicol Environ Health Sci, doi:10.1007/s13530-020-00056-4
Rothwell, None, The Journal of Biological Databases and Curation
Ruswanto, Wulandari, Rahayu, Mardaningrum, Hidayati, None, Pharmacosricpt
Santos, Ferreira, Caffarena, None, Methods in Molecular Biology, doi:10.1007/978-1-4939-9752-7_2
Shafhan Arfi, Lestari, Damayanti, None
Suhartati, Anugrah, Raharja, None
Syarif, None, Jurnal Kedokteran Brawijaya, doi:10.21776/ub.jkb.2016.029.01.7
Tung, Nham, Hai, Thu, None
Wang, None, RSC Adv, doi:10.1039/C6RA28442F
Wolfram, Trifan, None, Computational Phytochemistry
Wu, Ta, Lung, Weng, Leong, None, Pharmaceutics
Zeng, Deng, Dang, Yu, None, Sci Rep
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit